The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wednesday broker round-up UPDATE

Wed, 22nd May 2013 09:37

Afferro Mining: Panmure Gordon reduces target price from 279p to 100p, while keeping its buy recommendation.Amara Mining: Westhouse Securities cuts target price from 110p to 90p retaining a buy recommendation.Amlin: Westhouse Securities moves target price from 455p to 470p and upgrades to add.ARM Holdings: Berenberg increases target price from 1150p to 1350p and maintains a buy recommendation.Beazley: Westhouse Securities shifts target price from 235p to 245p, while downgrading to neutral.Britvic: Investec places both its target price (prev.: 447p) and its buy recommendation under review.Burberry: JP Morgan increases target price from 1320p to 1400p and keeps a neutral rating. Deutsche Bank raises target price from 1400p to 1530p, while its hold recommendation remains unchanged. Credit Suisse ups target price from 1550p to 1600p and maintains an outperform rating.Capita Group: Investec ups target price from 865p to 1000p upgrading from sell to hold. HSBC Holdings increases target price from 775p to 1050p upgrading to neutral.Carnival: Morgan Stanley reduces target price from 2400p to 2200p, while reiterating an equal-weight rating. Deutsche Bank cuts target price from 2780p to 2640p staying with its buy recommendation. Exane takes target price from 2400p to 2200p and retains a neutral rating. HSBC Holdings reduces target price from 2900p to 2500p and downgrades to neutral.Catlin Group: Westhouse Securities takes target price from 530p to 590p upgrading to add.Darty: Citi shifts target price from 39p to 47p, but still recommends selling. Exane moves target price from 50p to 65p and maintains a neutral rating. Societe Generale takes target price from 51p to 68p, while downgrading to hold.Faroe Petroleum: Jefferies lowers target price from 210p to 200p, while keeping its buy recommendation.First Group: Morgan Stanley cuts target price from 195p to 176p, while upgrading to equal-weight.GlaxoSmithKline: Exane raises target price from 1400p to 1500p, but keeps its underperform rating.Great Portland Estates: Investec increases target price from 515p to 630p, while reiterating an add rating.Griffin Mining: Cantor Fitzgerald ups target price from 40p to 70p and upgrades to buy.Hikma Pharmaceuticals: Credit Suisse takes target price from 820p to 1050p, while its outperform rating is kept.Hiscox: Westhouse Securities shifts target price from 530p to 540p and keeps a neutral rating.Hogg Robinson Group: Investec lowers target price from 100p to 95p, while maintaining its buy recommendation. Canaccord Genuity shifts target price from 90p to 85p and retains a buy recommendation.Homeserve: Jefferies ups target price from 210p to 240p keeping a hold recommendation.HSBC Holdings: Bank of America ups target price from 755p to 785p and reiterates a neutral rating.Imagination Technologies Group: Berenberg reduces target price from 360p to 250p and leaves its sell recommendation unchanged.Informa: Westhouse Securities downgrades from add to neutral with a target price of 525p.Innovation Group: Investec moves target price from 30p to 33p maintaining a buy recommendation. Panmure Gordon shifts target price from 38p to 39p and keeps a buy recommendation.Invensys: Exane raises target price from 350p to 380p reiterating a neutral rating.Kazakhmys: UBS reduces target price from 465p to 385p and downgrades from buy to neutral.Magnolia Petroleum: Northland Capital initiates with a target price of 4.60p and a buy recommendation.Man Group: Citi moves target price from 110p to 130p and retains a neutral rating.Marks & Spencer: Nomura increases target price from 500p to 540p maintaining a buy recommendation. Citi ups target price from 440p to 470p and stays with its neutral rating. Deutsche Bank moves target price from 450p to 465p and leaves its hold recommendation unaltered. Exane raises target price from 310p to 390p keeping an underperform rating. Societe Generale ups target price from 472p to 581p and retains a buy recommendation. HSBC Holdings takes target price from 390p to 490p and maintains a neutral rating.MITIE: Jefferies cuts target price from 300p to 285p and maintains a hold recommendation.NetDimensions: Panmure Gordon ups target price from 118p to 124p reiterating its buy recommendation.Novae Group: Westhouse Securities raises target price from 450p to 500p and retains a neutral rating.Optimal Payments: Canaccord Genuity takes target price from 200p to 220p and retains a buy recommendation.Optos: N+1 Singer reduces target price from 150p to 135p, while upgrading to hold.Paragon Group: JP Morgan moves target price from 300p to 361p maintaining an overweight rating.Petropavlovsk: Westhouse Securities lowers target price from 285p to 275p keeping its buy recommendation.PZ Cussons: Panmure Gordon increases target price from 380p to 400p and retains a hold recommendation.RPS Group: Jefferies lowers target price from 285p to 275p, while leaving its buy recommendation unchanged.Shaftesbury: Investec takes target price from 550p to 690p and retains a hold recommendation.UK Mail Group: Investec raises target price from 465p to 600p and stays with its buy recommendation.Vectura: JP Morgan shifts target price from 133p to 148p and stays with its overweight rating.
More News
22 Nov 2023 09:48

LONDON BROKER RATINGS: RBC cuts HSBC; Liberum cuts Glencore

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
21 Nov 2023 11:52

GSK to begin phase 3 trials of low-carbon Ventolin inhaler in 2024

(Alliance News) - GSK PLC on Tuesday said it will begin phase 3 trials of a low carbon version of its metered dose inhaler Ventolin using a "next generation" propellant in 2024.

Read more
14 Nov 2023 17:04

LONDON MARKET CLOSE: FTSE 100 underwhelms as stocks jump after US CPI

(Alliance News) - European equities jumped in the wake of a cooler-than-expected US inflation reading, which took some sting out of a recent hawkish reassessment of the Federal Reserve interest rate outlook.

Read more
13 Nov 2023 09:47

GSK hails momelotinib opinion from European Medicines Agency committee

(Alliance News) - GSK PLC on Monday announced that a European Medicines Agency panel has given a positive opinion recommending momelotinib to treat myelofibrosis patients with anaemia.

Read more
9 Nov 2023 15:50

UK dividends calendar - next 7 days

Friday 10 November 
Bodycote PLCdividend payment date
Breedon Group PLCdividend payment date
Chesnara PLCdividend payment date
Finsbury Growth & Income Trust PLCdividend payment date
Invesco Bond Income Plus Ltddividend payment date
JPMorgan Emerging Markets Investment Trust PLCdividend payment date
Kerry Group PLCdividend payment date
Merchants Trust PLCdividend payment date
Mid Wynd International Investment Trust PLCdividend payment date
Mid Wynd International Investment Trust PLCspecial dividend payment date
Montanaro UK Smaller Cos Investment Trust PLCdividend payment date
Senior PLCdividend payment date
Spectris PLCdividend payment date
Spirax-Sarco Engineering PLCdividend payment date
Travis Perkins PLCdividend payment date
Monday 13 November 
no events scheduled 
Tuesday 14 November 
no events scheduled 
Wednesday 15 November 
Coats Group PLCdividend payment date
Ferguson PLCdividend payment date
JP Morgan Mid Cap Investment Trust PLCdividend payment date
Strategic Equity Capital PLCdividend payment date
Thursday 16 November 
abrdn Property Income Trust Ltdex-dividend payment date
Asian Energy Impact Trust PLCex-dividend payment date
Baillie Gifford Japan Trust PLCex-dividend payment date
BlackRock Greater Europe Investment Trust PLCex-dividend payment date
Bunzl PLCex-dividend payment date
Bytes Technology Group PLCex-dividend payment date
Centrica PLCdividend payment date
Coca-Cola Europacific Partners PLCex-dividend payment date
DX Group PLCex-dividend payment date
Empiric Student Property PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
GCP Asset Backed Income Fund Ltdex-dividend payment date
GSK PLCex-dividend payment date
Hargreaves Lansdown PLCex-dividend payment date
Henderson Opportunities Trust PLCex-dividend payment date
ICG Enterprise Trust PLCex-dividend payment date
James Halstead PLCex-dividend payment date
Lancashire Holdings Ltdspecial ex-dividend payment date
Majedie Investments PLCex-dividend payment date
Marks & Spencer Group PLCex-dividend payment date
Murray Income Trust PLCex-dividend payment date
New Star Investment Trust PLCex-dividend payment date
NextEnergy Solar Fund Ltdex-dividend payment date
Octopus Renewables Infrastructure Trust PLCex-dividend payment date
Pershing Square Holdings Ltdex-dividend payment date
Personal Group Holdings PLCdividend payment date
Redrow PLCdividend payment date
Regional REIT Ltdex-dividend payment date
Schroder Oriental Income Fund Ltdex-dividend payment date
Scottish American Investment Co PLCex-dividend payment date
SCS Group PLCex-dividend payment date
Shell PLCex-dividend payment date
Supermarket Income REIT PLCdividend payment date
UK Commercial Property REIT Ltdex-dividend payment date
Unilever PLCex-dividend payment date
Wincanton PLCex-dividend payment date
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
8 Nov 2023 09:30

LONDON BROKER RATINGS: UBS downbeat on AJ Bell and Hargreaves Lansdown

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
2 Nov 2023 10:14

LONDON BROKER RATINGS: Bank of America starts Unite Group with 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 Nov 2023 16:52

LONDON MARKET CLOSE: Stocks prosper ahead of central bank rate calls

(Alliance News) - Stocks in London took their lead from a positive start on Wall Street to close higher as investors prepare for interest rate decisions in the UK and US.

Read more
1 Nov 2023 16:35

London close: Stocks rise ahead of US Fed policy decision

(Sharecast News) - London's stock market finished in positive territory on Wednesday, with investors keeping a keen eye on the upcoming policy announcement from the US Federal Reserve.

Read more
1 Nov 2023 08:51

TOP NEWS: GSK ups guidance as boosted by Shingrix and Arexvy

(Alliance News) - GSK PLC on Wednesday hailed the performance of the world's first approved respiratory syncytial virus vaccine Arexvy, as it reported a rise in profit and revenue.

Read more
1 Nov 2023 08:50

LONDON MARKET OPEN: FTSE 100 up, FTSE 250 down as Aston Martin tumbles

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of key central bank decisions, as investors were cheered by some strong updates from large-cap listings.

Read more
1 Nov 2023 07:40

LONDON BRIEFING: GSK raises annual guidance following Arexvy launch

(Alliance News) - Stocks in London are called higher on Wednesday, with the main focal point for the day being the upcoming US interest rate decision.

Read more
1 Nov 2023 07:27

GSK hikes guidance after strong third quarter

(Sharecast News) - GSK announced a robust third quarter on Wednesday, prompting an upgrade to its full-year guidance.

Read more
30 Oct 2023 09:01

IN BRIEF: GSK says Jemperli meets endpoint in endometrial cancer trial

GSK PLC - Brentford, west London-based pharmaceutical maker - Jemperli, whose generic name is dostarlimab, meets endpoint of overall survival in phase III Ruby trial on adult patients with primary advanced or recurrent endometrial cancer. Jemperli, combined with standard-of-care chemotherapy, followed by dostarlimab, demonstrated a "statistically significant and clinically meaningful benefit" to the patients in the trial.

Read more
30 Oct 2023 07:06

GSK's Jemperli sees success in endometrial cancer trial

(Sharecast News) - GSK reported encouraging outcomes from part one of the 'RUBY' phase three trial evaluating the efficacy of 'Jemperli', or dostarlimab, with standard chemotherapy for treating adult patients with advanced or recurrent endometrial cancer on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.